In fact, the Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022 [15,16] recommends that, if proteinuria occurs during VEGF inhibitor treatment, it is important to decide whether to interrupt or discontinue treatment after comprehensive evaluation of renal function and serum albumin levels, not just solely relying on the severity of proteinuria based on UPCR. Here, VEGFA is linked to kidney injury.